The Department of Medicine is seeking a highly motivated physician with training in Pulmonary Medicine for an academic clinician faculty position at the Assistant, Associate, or Attending rank. This role is focused on onco-pulmonology and the clinical care of patients with cancer who develop pulmonary complications related to malignancy, cancer therapy, immune-based treatments, transplantation, infection, and underlying chronic lung disease. The Pulmonary Service provides specialized expertise in Onco-Pulmonary and General Pulmonary Medicine, with an emphasis on longitudinal, multidisciplinary oncologic care; management of immunocompromised hosts; evaluation and treatment of drug-induced and radiation-induced pneumonitis; pulmonary complications of cellular therapy and stem cell transplantation; peri-operative pulmonary risk assessment; and chronic lung diseases including COPD, asthma, interstitial lung disease, bronchiectasis, pulmonary nodules, and chronic cough.
The successful candidate will have the opportunity to help grow MSK’s multidisciplinary immune-related adverse event (IRAE) program, with a particular focus on pulmonary toxicities from immune checkpoint inhibitors and other novel cancer therapies. The position includes robust clinical and research opportunities to build collaborative programs across the Department of Medicine, including partnerships with solid tumor oncology, hematologic malignancies, subspecialty medicine, radiology, pathology, infectious diseases, rheumatology, dermatology, cardiology, critical care, and supportive care. We are particularly interested in candidates who wish to expand clinical research and clinical trials focused on pulmonary toxicities, IRAEs, and multidisciplinary models of care for patients receiving advanced oncologic therapies.
Pulmonary hosts two fellowships, one in Pulmonary & Critical Care Medicine and the other in Interventional Pulmonology and collaborate with an integrated Pulmonary APP inpatient team. The Pulmonary research portfolio continues to expand in breadth, with active publications, new prospective clinical trials and external funding.